Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

除了电子设备和仪器、集成电路，医疗保健、工业机械、电子元件等板块也获得了较多外资机构的关 注。百济神州、汇川技术、新产业、深南电路等行业龙头接受外资调研的次数位居前列。 ◎记者 王彭 据统计，5月以来，200余家外资机构现身A股上市公司调研名单，累计调研逾500次。具体而言，以电 子设备和仪器、集成电路为代表的硬科技领域是外资关注的焦点。 Wind数据显示，截至6月4日，5月以来共有222家外资机构调研了185家A股公司，累计调研532次。在这 份调研名单上，高盛、富达、贝莱德、瑞银、安联、Point72等机构频频现身。在接受外资机构调研的 行业中，代表硬科技领域的电子设备和仪器、集成电路等板块获得最多外资机构的关注。据统计，奥普 特、澜起科技、沪电股份、奥比中光等公司均吸引了30家以上外资机构的调研。 以澜起科技为例，公司5月29日披露了一份投资者关系活动记录表，瑞银、安联、富达、Point72等知名 外资机构均现身调研名单；沪电股份近日披露的投资者关系活动记录表显示，贝莱德、富达、高盛、摩 根大通等外资机构参与了公司5月19日的特定对象调研。 被称为"华尔街最疯狂的赚钱机器"的Point72在此期间调研1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年5月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二名承授人授出可認 購合共21,140股美國存託股份的購股權並向三百六十八名承授人授出涉及合共 54,538股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2025年5月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二名 承授人可認購合共21,140股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： 授出日期： 2025年5月30日 承授人數目： 二名 授出購股權及受限制股份單位 已授出購股權涉及的相關股份數目： 274,820 購股權總數（美國存託股份）: 21,140 因已授出購股權獲行使而可予 ...

Group 1 - The market experienced a rebound on June 4, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.15 trillion yuan, an increase of 11.6 billion yuan compared to the previous trading day [1] - The innovative drug concept remained active, with the Tianhong Innovative Drug ETF (517380) closing up 2.34%, reaching a peak price of 0.660 yuan, the highest since November 2023, and achieving a trading volume of nearly 20 million yuan, a two-year high [1] - The Tianhong Innovative Drug ETF (517380) has seen a year-to-date increase of 25.96% as of June 4, ranking first among all industry ETFs in the market [1] Group 2 - Changjiang Securities indicated that the valuation level of domestic innovative drugs is low, and some products have the potential to be the best in their class globally, supporting the outlook for innovative drugs to expand internationally and achieve premium valuations [2] - Guojin Securities emphasized that innovative drugs and certain semi-innovative drugs are key investment focuses, with upcoming policy changes and data releases expected to catalyze stock price movements [2] - Huafu Securities reported that the total transaction amount for innovative drug BD from 2020 to 2024 increased from 9.2 billion USD to 52.3 billion USD, with the upfront payment amount rising from 600 million USD to 4.1 billion USD [2]

6月4日，创新药概念继续活跃，相关ETF中，创新药ETF天弘(517380)截至发稿涨2.81%，盘中价格最 高触及0.660元，创2023年11月以来新高。成分股中，信达生物涨超15%，皓元医药、泰格医药、中国 生物制药等涨幅均在6%以上。 消息面上，据新华社消息，2025年1至5月，国家药品监督管理局批准20余款1类创新药上市，数量刷新 近五年同期纪录；2025年美国临床肿瘤学会（ASCO）年会上，70余项中国原创研究成果入选。近来， 国内创新药上市跑出加速度，药企源头创新与国际竞争力同步跃升。业内人士认为，我国创新药领域已 从过去的"跟随式创新"逐步迈向"全球领跑"。中国药企紧紧围绕临床价值核心，在肿瘤靶向、免疫治疗 等关键赛道发力，正悄然改写全球医药格局。 中邮证券认为，创新药板块近期具备较多催化，海外BD、ASCO大会等事件持续提高板块热度。国内 创新药企迎来估值重塑，有望成为贯穿全年的投资主线。下半年国家医保谈判为重要事件，谈判前成功 获批上市创新药有望通过国谈进入医保实现加速放量。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 拉长时间来看， ...

Group 1 - The Hong Kong Technology ETF (513560) has shown strong performance, with a recent increase of 1.96% and a trading volume of 60.53 million yuan, indicating active market participation [2] - The index it tracks, the CSI Hong Kong Stock Connect Technology Index (931573), has seen significant gains, with notable increases in constituent stocks such as Innovent Biologics (01801) up 16.22% and Zai Lab (09688) up 7.45% [2] - The average daily trading volume of the Hong Kong Technology ETF since the beginning of 2025 is 445 million yuan, reflecting robust trading activity [2] Group 2 - The Hong Kong Technology ETF has reached a new high in scale at 524 million yuan, with a recent increase of 16 million shares over the past week, ranking second among comparable funds [3] - Over the past year, the net value of the Hong Kong Technology ETF has increased by 59.78%, placing it first among comparable funds [3] - The ETF has demonstrated a historical return capability, with a maximum monthly return of 26.15% and an average monthly return of 8.83% [3] Group 3 - The Hong Kong Technology ETF has a management fee of 0.50% and a custody fee of 0.10%, contributing to its overall cost structure [4] - The ETF's tracking error over the past three months is 0.213%, indicating the highest tracking precision among comparable funds [4] - The current price-to-earnings ratio (PE-TTM) of the CSI Hong Kong Stock Connect Technology Index is 21.9, which is below 94.42% of the historical data over the past year, suggesting a low valuation [4] Group 4 - The top ten weighted stocks in the CSI Hong Kong Stock Connect Technology Index account for 71.48% of the index, with major companies including Xiaomi (01810), BYD (01211), and Alibaba (09988) [4] - Investors without stock accounts can access the Hong Kong Technology ETF through linked funds, providing an opportunity to invest in the innovative pharmaceutical sector [6]

Group 1 - The Chinese innovative pharmaceutical industry is experiencing an unprecedented revaluation, with the innovative drug index rising over 20% and the Hong Kong innovative drug index increasing by more than 45% this year [1][2] - Institutions have shown heightened interest in the innovative drug sector, with numerous companies such as BeiGene and I-Mab being heavily researched by various institutions [1][3] - The focus of institutional research has shifted from generic drugs and raw materials to cutting-edge areas like ADCs, bispecific antibodies, and cell therapies, indicating a growing interest in clinical data and international progress [4][5] Group 2 - The recent surge in the innovative drug sector is attributed to the culmination of years of investment and development, with many projects now reaching commercialization [5][6] - The improvement in liquidity and the influx of foreign capital have significantly boosted the performance of Hong Kong innovative drug stocks, with net purchases exceeding 600 billion yuan this year [6][7] - The next three years are expected to be critical for the Chinese innovative drug industry, with 2025 marking a pivotal year for revenue growth, profitability, and valuation increases [8][9] Group 3 - The innovative drug sector is anticipated to remain a key focus within the pharmaceutical industry, with particular attention on companies that are successfully entering overseas markets and those that are experiencing significant domestic sales growth [9]

Summary of Key Points Core Viewpoint - The June stock recommendations from 42 brokerage firms show a significant increase in the number of recommended stocks, with the pharmaceutical and biotechnology sector returning to the top of the industry recommendation rankings after three years, indicating a renewed market interest in cyclical industries [1][3]. Stock Recommendations - A total of 332 stocks received 457 recommendations, with 42 stocks from the ChiNext gaining 53 recommendations, 45 stocks from the STAR Market receiving 59 recommendations, and 43 Hong Kong stocks getting 62 recommendations, marking an increase of 6 and 7 stocks respectively compared to the previous month [1]. - Six stocks received recommendations from five brokerage firms: China Merchants Bank, Yara International, Smoore International, SF Holding, Qingdao Beer, and Haida Group [1]. - Six stocks received recommendations from four brokerage firms: Zijin Mining, China Mobile, Zhenhua Heavy Industries, Tencent Holdings, Hangzhou Bank, and Dongpeng Beverage [1]. Industry Rankings - The pharmaceutical and biotechnology sector achieved a recommendation rate of 10.2%, reclaiming the top position, while the electronics sector fell to second place with a recommendation rate of 9.3% [3]. - The food and beverage sector ranked third with a recommendation rate of 6.58%, and the machinery equipment sector ranked fourth with a rate of 6.35% [3]. - The coal industry saw a significant increase in recommendation rate by 59.6%, while the transportation sector increased by 52.1%, indicating a positive outlook for these industries [3]. Declining Industry Interest - The retail trade sector experienced a notable decline in recommendation rate by 43.17%, attributed to renewed trade tensions and previous excessive price increases [4]. - The defense and military industry saw a decrease of 34.77%, mainly due to the easing of the Russia-Ukraine situation [4]. - The automotive sector's recommendation rate dropped by 30.99%, reflecting concerns over industry competition [4]. Performance of Brokerage Recommendations - In May, 30 out of 45 brokerage firms reported positive returns, with the top performers being Guoyuan Securities (6.28%) and Caitong Securities (5.93%) [5][6]. - As of May 30, 36 out of 45 brokerage firms had positive returns for the year, with 16 firms achieving returns close to or exceeding 10% [6]. Market Outlook - Analysts suggest that June will see continued improvement in returns and win rates, with a focus on large-cap growth stocks, although the market is expected to remain volatile [7]. - The market sentiment has been affected by fluctuating U.S. tariff policies and slow progress in U.S.-China trade negotiations, which are key factors influencing market risk appetite [7].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].

Core Viewpoint - The article discusses the structural differentiation in the current stock market, highlighting the significant performance gap between A-shares and Hong Kong stocks, driven by foreign capital inflow, the weight advantage of technology stocks, and differing policy expectations [2][3]. A-share High Dividend Portfolio: Stable Foundation for Value Reassessment - Financial Performance and Dividend Capability: In a low-interest and volatile market, high-dividend companies are preferred for their stable cash flow and shareholder returns. The total dividend of central state-owned enterprises is expected to reach 1.17 trillion yuan in 2024, accounting for 50% of the total A-share dividends [4][5]. - Key Companies: China Shenhua is expected to have a dividend yield of over 5.9% in 2024, while Huaneng International plans a dividend payout ratio of at least 50% of distributable profits. Wuliangye and Muyuan Foods are also highlighted for their strong financial performance and dividend potential [4][5][6]. - Competitive Moat: The sustainability of the high-dividend portfolio relies on the companies' competitive advantages, including cost advantages in the energy sector and brand differentiation in consumer goods [6]. - Market Outlook: The core opportunities for the high-dividend portfolio in 2025 include the resonance of declining interest rates and stable growth policies, with specific catalysts in the energy and consumer sectors [7]. Hong Kong Growth Portfolio: Profit Elasticity and Industry Wave Resonance - Financial Performance and Growth Momentum: The Hong Kong portfolio focuses on internet, consumer, and innovative pharmaceutical sectors, benefiting from global liquidity easing and AI breakthroughs. Meituan's revenue is expected to reach 337.6 billion yuan in 2024, with a net profit increase of 158.4% [8][9]. - Competitive Moat: The growth portfolio's moat is derived from network effects, research and development accumulation, and global capabilities, with companies like Tencent and Meituan leveraging their ecosystems [10]. - Market Outlook: The core opportunities for the Hong Kong growth portfolio in 2025 are driven by global liquidity easing and clear industry policy catalysts, particularly in AI applications and innovative pharmaceuticals [11]. Comparison of Portfolios and Investor Preferences - Market Performance and Fund Flows: Investors are currently favoring the Hong Kong growth portfolio due to significant performance differences, with the Hang Seng Index rising 16.1% compared to the -2.41% decline of the CSI 300 [13][14]. - Investor Structure Preference: The high-dividend portfolio attracts conservative investors such as insurance funds, while the growth portfolio appeals to foreign capital and growth-oriented funds [15][16]. - Current Popularity Assessment: The Hong Kong growth portfolio is more favored due to its higher earnings growth rate and alignment with global technology trends, while the high-dividend portfolio remains attractive for risk-averse investors [16][17].